Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...

The study of more than two million veterans with diabetes details GLP-1 RA use relating to 175 outcomes; without ...

Insights from a study on GLP-1 receptor agonists reveal benefits for cardiometabolic health, with notable risks for ...

Surgery is the gold standard, GLP-1s are all the rage—whether a head-to-head study is needed depends on who you ask.

Caissa Troutman, MD By comparison, non-pharmacological caloric ... Anila Chadha, MD, recommends that patients on GLP-1 agonists aim for 30 g of protein at every meal and emphasize both protein ...

Early research suggests GLP-1 drugs could prevent or treat Alzheimer's Disease. Results from a big clinical trial could soon ...

Novo Nordisk’s amycretin shows 22% weight loss over 36 weeks, potentially surpassing Eli Lilly’s Zepbound. Further trials are ...

LEXX READ THE FULL LEXX RESEARCH REPORT Lexaria Bioscience Corporation (NASDAQ:LEXX) reported fiscal first quarter 2025 ...

A study on GLP1RA medications found that behavioral side effects likely do not result from direct action on GLP1R.

Hers shares information about the average weight for women in the U.S., what women believe the ideal weight is, and the ...